SAN FRANCISCO--(BUSINESS WIRE)--Insert after sixth paragraph of release: HYPERSCAN has not been cleared by the USFDA for clinical use.
The corrected release reads:
MEVION MEDICAL SYSTEMS INTRODUCES HYPERSCAN FOR THE MEVION S250 PLATFORM
Device is the world’s first proton therapy system capable of delivering pencil beam scanning at hyper speed
Mevion Medical Systems is again advancing the delivery of cancer care with the introduction of HYPERSCAN for the MEVION S250, the only modular, single room proton therapy system. Benefiting from direct and efficient proton beam generation, HYPERSCAN’s patented technology allows radiation to be precisely delivered using a sharp beam of radiation, with the tumor being volumetrically scanned in a matter of seconds. Current pencil beam delivery systems are known to be sensitive to motion which can result in higher treatment uncertainties. HYPERSCAN’s fast beam delivery is much less sensitive to patient and tumor motions, thus delivering a more robust treatment.
“HYPERSCAN enables treatment with fine precision at tremendous speed and with uncompromised beam quality,” said Joseph K. Jachinowski, president and chief executive officer of Mevion Medical Systems. “This new technological advance will help providers deliver the best possible cancer care to the patients who need it most.”
HYPERSCAN is debuting at the 56th annual meeting of the American Society for Radiation Oncology (ASTRO), held September 14 – 16 in San Francisco. Mevion representatives will formally introduce HYPERSCAN at booth 728 in the exhibit hall.
HYPERSCAN is built on the MEVION S250 proton therapy platform that has been operating clinically since December 2013. The HYPERSCAN system features rapid volumetric and layer rescanning, a streamlined image-based clinical workflow, sub-millimeter position tracking, and beam gating connectivity.
Simultaneously, Mevion is announcing it has reached an agreement with a financial services provider to offer financing to customers interested in purchasing the MEVION S250. This will provide Mevion’s customers with an alternative to traditional financing structures, should they desire it.
“The introduction of HYPERSCAN technology and the availability of alternative financing is a demonstration of Mevion’s continued commitment to improving the worldwide availability and clinical use of proton therapy,” said Jachinowski. “Mevion is dedicated to removing the obstacles of size, complexity and cost that exist with conventional proton therapy systems and making proton therapy as accessible as possible to the cancer patients who need it.”
HYPERSCAN has not been cleared by the USFDA for clinical use.
High Resolution Images Available
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion’s flagship product, the MEVION S250 proton therapy platform, is the only modular, single room proton therapy system currently on the market. The MEVION S250 integrates with standard radiation therapy workflow and provides a proton therapy treatment environment at a fraction of the cost, footprint and operational complexity of conventional systems.
Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan. For more information, please visit www.mevion.com.